GYRE GYRE THERAPEUTICS, INC.
Nasdaq · SEC CIK 1124105 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $952.9K 9 sales by 2 insiders
- Filings on record
- 137 since 2021-07-02, latest 2026-08-04 20:45
BoughtSold
Transactions 99
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-06-22 16:02 | 2026-06-09+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +11.0K | 703.0K | +2% | +$8,250 |
| DM | 2026-06-22 16:02 | 2026-06-09+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.25 | -11.0K | 700.0K | -2% | -$68.7K |
| D | 2026-06-15 16:01 | 2026-06-11 | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +2,800 | 702.8K | +0.4% | +$2,100 |
| D | 2026-06-15 16:01 | 2026-06-11 | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.17 | -2,800 | 700.0K | -0.4% | -$17.3K |
| DM | 2026-06-11 16:01 | 2026-06-09+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +20.9K | 706.4K | +3% | +$15.7K |
| DM | 2026-06-11 16:01 | 2026-06-09+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.16 | -20.9K | 700.0K | -3% | -$128.9K |
| DM | 2026-06-08 16:01 | 2026-06-04+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +35.0K | 715.4K | +5% | +$26.2K |
| DM | 2026-06-08 16:01 | 2026-06-04+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.25 | -35.0K | 700.0K | -5% | -$218.6K |
| DM | 2026-05-27 16:01 | 2026-05-22+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +7,500 | 704.0K | +1% | +$5,625 |
| DM | 2026-05-27 16:01 | 2026-05-22+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.09 | -7,500 | 700.0K | -1% | -$45.7K |
| DM | 2026-05-22 18:19 | 2026-05-20+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +22.2K | 712.8K | +3% | +$16.7K |
| DM | 2026-05-22 18:19 | 2026-05-20+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.15 | -22.2K | 700.0K | -3% | -$136.7K |
| DM | 2026-05-20 16:01 | 2026-05-18+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +9,320 | 709.1K | +1% | +$6,990 |
| DM | 2026-05-20 16:01 | 2026-05-18+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.38 | -9,320 | 700.0K | -1% | -$59.4K |
| DM | 2026-05-18 16:01 | 2026-05-14+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +28.7K | 713.1K | +4% | +$21.5K |
| DM | 2026-05-18 16:01 | 2026-05-14+ | GYRE | Ye Weiguo | COO | S - Sale+OE | $6.79 | -28.7K | 700.0K | -4% | -$194.8K |
| MTI | 2026-05-07 21:58 | 2026-05-05+ | GYRE | Luo Ying | CEO, Dir | S - Sale | $8.04 | -10.3K | 2.57M | -0.4% | -$82.9K |
| MTI | 2025-05-29 | 2025-05-27+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.23 | -2,558 | 2.81M | -0.1% | -$26.2K |
| MTI | 2025-05-27 | 2025-05-22+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.91 | -2,182 | 2.81M | -0.1% | -$23.8K |
| MTI | 2025-05-22 | 2025-05-20+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.04 | -4,000 | 2.81M | -0.1% | -$44.2K |
| MTI | 2025-05-20 | 2025-05-16+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.21 | -4,000 | 2.82M | -0.1% | -$44.8K |
| MTI | 2025-05-16 | 2025-05-14+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.69 | -2,020 | 2.82M | -0.1% | -$21.6K |
| MTI | 2025-05-14 | 2025-05-12+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.96 | -4,000 | 2.82M | -0.1% | -$43.9K |
| D | 2025-05-14 | 2025-04-01 | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +50.0K | 700.0K | +8% | +$37.5K |
| DM | 2025-04-25 | 2025-03-24+ | GYRE | Ye Weiguo | COO | M - OptEx | $0.75 | +650.0K | 300.0K | New | +$487.5K |
| D | 2025-04-18 | 2025-04-16 | GYRE | Eastling Thomas Wilson | Dir | M - OptEx | $6.93 | +15.0K | 15.0K | New | +$104.0K |
| TI | 2025-03-25 | 2025-03-21 | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.00 | -174 | 2.82M | -0.0% | -$1,740 |
| MTI | 2025-03-21 | 2025-03-19+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.11 | -4,000 | 2.83M | -0.1% | -$40.4K |
| MTI | 2025-03-19 | 2025-03-17+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.89 | -2,242 | 2.83M | -0.1% | -$26.7K |
| MTI | 2025-03-17 | 2025-03-13+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.05 | -4,000 | 2.83M | -0.1% | -$48.2K |
| MTI | 2025-03-13 | 2025-03-11+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.57 | -4,000 | 2.84M | -0.1% | -$46.3K |
| MTI | 2025-03-11 | 2025-03-07+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.19 | -4,000 | 2.84M | -0.1% | -$40.8K |
| MTI | 2025-03-07 | 2025-03-05+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.89 | -4,000 | 2.85M | -0.1% | -$43.6K |
| MTI | 2025-03-05 | 2025-03-03+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.04 | -4,000 | 2.85M | -0.1% | -$44.2K |
| MTI | 2025-03-03 | 2025-02-27+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.37 | -4,000 | 2.85M | -0.1% | -$45.5K |
| MTI | 2025-02-27 | 2025-02-25+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.50 | -4,000 | 2.86M | -0.1% | -$46.0K |
| MTI | 2025-02-25 | 2025-02-21+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.30 | -4,000 | 2.86M | -0.1% | -$45.2K |
| MTI | 2025-02-21 | 2025-02-19+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.35 | -4,000 | 2.86M | -0.1% | -$49.4K |
| MTI | 2025-02-19 | 2025-02-14+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.21 | -4,000 | 2.87M | -0.1% | -$48.9K |
| MTI | 2025-02-14 | 2025-02-12+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.59 | -4,000 | 2.87M | -0.1% | -$46.4K |
| MTI | 2025-02-12 | 2025-02-10+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.72 | -3,878 | 2.88M | -0.1% | -$45.4K |
| MTI | 2025-02-11 | 2025-02-06+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.51 | -4,000 | 2.88M | -0.1% | -$50.0K |
| MTI | 2025-02-06 | 2025-02-04+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.01 | -4,000 | 2.88M | -0.1% | -$48.0K |
| MTI | 2025-02-04 | 2025-01-31+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.49 | -4,000 | 2.89M | -0.1% | -$46.0K |
| MTI | 2025-01-31 | 2025-01-29+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.40 | -4,000 | 2.89M | -0.1% | -$45.6K |
| MTI | 2025-01-29 | 2025-01-27+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.35 | -4,000 | 2.90M | -0.1% | -$45.4K |
| MTI | 2025-01-27 | 2025-01-23+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.69 | -4,000 | 2.90M | -0.1% | -$42.8K |
| MTI | 2025-01-24 | 2025-01-21+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.74 | -4,000 | 2.90M | -0.1% | -$43.0K |
| MTI | 2025-01-21 | 2025-01-16+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.71 | -4,000 | 2.91M | -0.1% | -$42.9K |
| MTI | 2025-01-16 | 2025-01-14+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.62 | -4,000 | 2.91M | -0.1% | -$42.5K |
| MTI | 2025-01-14 | 2025-01-10+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.02 | -1,113 | 2.92M | -0.0% | -$11.2K |
| ATI | 2025-01-10 | 2025-01-03 | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.85 | -833 | 2.92M | -0.0% | -$9,871 |
| MTI | 2025-01-08 | 2025-01-06+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.08 | -2,216 | 2.92M | -0.1% | -$22.3K |
| MTI | 2025-01-06 | 2024-01-03+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.89 | -4,000 | 2.92M | -0.1% | -$47.5K |
| MTI | 2025-01-02 | 2024-12-30+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.40 | -4,000 | 2.92M | -0.1% | -$49.6K |
| MTI | 2024-12-30 | 2024-12-26+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.64 | -4,000 | 2.93M | -0.1% | -$50.6K |
| MTI | 2024-12-26 | 2024-12-23+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $12.10 | -4,000 | 2.93M | -0.1% | -$48.4K |
| MTI | 2024-12-23 | 2024-12-19+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $10.86 | -4,000 | 2.94M | -0.1% | -$43.4K |
| MTI | 2024-12-19 | 2024-12-17+ | GYRE | Ma Songjiang | Pres, Dir | S - Sale | $11.21 | -4,000 | 2.94M | -0.1% | -$44.9K |
| DT | 2024-07-01 | 2024-06-28 | GYRE | USMAN NASSIM | Dir | M - OptEx | $6.93 | +3,452 | 5,088 | +211% | +$23.9K |
| DT | 2024-07-01 | 2024-06-28 | GYRE | USMAN NASSIM | Dir | S - Sale+OE | $12.00 | -3,452 | 1,636 | -68% | -$41.4K |
| DMT | 2024-05-02 | 2024-05-01 | GYRE | USMAN NASSIM | Dir | S - Sale+OE | $14.13 | -20.0K | 6,736 | -75% | -$282.6K |
| DT | 2024-05-02 | 2024-05-01 | GYRE | USMAN NASSIM | Dir | M - OptEx | $6.93 | +20.0K | 21.6K | +1,222% | +$138.6K |
| DT | 2024-04-03 | 2024-04-01 | GYRE | USMAN NASSIM | Dir | M - OptEx | $6.93 | +20.0K | 21.6K | +1,222% | +$138.6K |
| DT | 2024-04-03 | 2024-04-01 | GYRE | USMAN NASSIM | Dir | S - Sale+OE | $16.15 | -20.0K | 1,636 | -92% | -$323.0K |
| DT | 2024-03-19 | 2024-03-15 | GYRE | USMAN NASSIM | Dir | S - Sale+OE | $17.26 | -20.0K | 1,636 | -92% | -$345.2K |
| DT | 2024-03-19 | 2024-03-15 | GYRE | USMAN NASSIM | Dir | M - OptEx | $6.93 | +20.0K | 21.6K | +1,222% | +$138.6K |
| I | 2023-11-22 | 2023-10-30 | GYRE | GNI USA, Inc. | 10% | J - Other | — | +63.59M | 64.01M | +15,221% | — |
| DI | 2023-11-22 | 2023-10-30 | GYRE | Luo Ying | Dir | J - Other | — | +2.84M | 2.84M | New | — |
| D | 2023-10-27 | 2023-10-27 | GYRE | GNI Hong Kong Ltd | 10% | J - Other | — | -5.37M | 0 | -100% | — |
| M | 2023-09-01 | 2023-08-31 | GYRE | GNI Hong Kong Ltd | 10% | D - Sale to Iss | — | -6,267 | 0 | -100% | — |
| 2023-09-01 | 2023-08-31 | GYRE | Miller Seline E. | SVP Fin, Interim CFO, PAO | D - Sale to Iss | — | -6.50 | 0 | -100% | — | |
| I | 2023-09-01 | 2023-08-31 | GYRE | LAWLOR AUGUSTINE | Dir | D - Sale to Iss | — | -24.22 | 0 | -100% | — |
| 2023-09-01 | 2023-08-31 | GYRE | LAWLOR AUGUSTINE | Dir | D - Sale to Iss | — | -24.57 | 0 | -100% | — | |
| MI | 2023-09-01 | 2023-08-31 | GYRE | USMAN NASSIM | Pres, CEO, Dir | D - Sale to Iss | — | -9.63 | 0 | -100% | — |
| 2023-09-01 | 2023-08-31 | GYRE | USMAN NASSIM | Pres, CEO, Dir | D - Sale to Iss | — | -24.54 | 0 | -100% | — | |
| 2023-09-01 | 2023-08-31 | GYRE | Hunt Andrea | Dir | D - Sale to Iss | — | -28.23 | 0 | -100% | — | |
| 2022-08-10 | 2022-08-09 | GYRE | Miller Seline E. | SVP Fin, Interim CFO, PAO | P - Purchase | $0.47 | +3,250 | 6,500 | +100% | +$1,528 | |
| 2022-08-10 | 2022-08-09 | GYRE | Blouse Grant E. | CSO | P - Purchase | $0.47 | +3,250 | 9,417 | +53% | +$1,528 | |
| 2022-08-10 | 2022-08-09 | GYRE | USMAN NASSIM | Pres, CEO, Dir | P - Purchase | $0.47 | +3,250 | 24.5K | +15% | +$1,528 | |
| 2022-02-16 | 2022-02-09 | GYRE | Miller Seline E. | SVP Fin, Interim CFO, PAO | P - Purchase | $0.46 | +3,250 | 3,250 | New | +$1,495 | |
| 2022-02-16 | 2022-02-09 | GYRE | USMAN NASSIM | Pres, CEO, Dir | P - Purchase | $0.46 | +3,250 | 21.3K | +18% | +$1,495 | |
| 2022-02-16 | 2022-02-09 | GYRE | Blouse Grant E. | CSO | P - Purchase | $0.46 | +3,250 | 6,167 | +111% | +$1,495 | |
| 2022-01-07 | 2022-01-07 | GYRE | Ling Geoffrey M.D. | Dir | A - Grant | $0.00 | +12.9K | 31.8K | +68% | $0 | |
| 2022-01-07 | 2022-01-07 | GYRE | Hunt Andrea | Dir | A - Grant | $0.00 | +7,521 | 28.2K | +36% | $0 | |
| 2022-01-07 | 2022-01-07 | GYRE | Williams Eddie | Dir | A - Grant | $0.00 | +12.3K | 34.8K | +55% | $0 | |
| 2021-10-05 | 2021-10-01 | GYRE | Williams Eddie | Dir | A - Grant | $0.00 | +2,980 | 22.5K | +15% | $0 | |
| 2021-10-05 | 2021-10-01 | GYRE | LAWLOR AUGUSTINE | Dir | A - Grant | $0.00 | +5,839 | 24.6K | +31% | $0 | |
| 2021-10-05 | 2021-10-01 | GYRE | Hunt Andrea | Dir | A - Grant | $0.00 | +1,824 | 20.7K | +10% | $0 | |
| 2021-10-05 | 2021-10-01 | GYRE | Ling Geoffrey M.D. | Dir | A - Grant | $0.00 | +2,858 | 18.9K | +18% | $0 | |
| 2021-10-05 | 2021-10-01 | GYRE | DESOUZA ERROL B | Dir | A - Grant | $0.00 | +3,588 | 29.8K | +14% | $0 | |
| 2021-08-11 | 2021-08-09 | GYRE | Levy Howard | Chief Medical Off | P - Purchase | $3.62 | +639 | 639 | New | +$2,313 | |
| 2021-08-11 | 2021-08-09 | GYRE | Blouse Grant E. | CSO | P - Purchase | $3.62 | +1,163 | 2,917 | +66% | +$4,210 | |
| 2021-08-11 | 2021-08-09 | GYRE | USMAN NASSIM | Pres, CEO, Dir | P - Purchase | $3.62 | +867 | 18.0K | +5% | +$3,139 | |
| D | 2021-07-02 | 2021-07-01 | GYRE | LAWLOR AUGUSTINE | Dir | A - Grant | $0.00 | +5,542 | 18.7K | +42% | $0 |
| D | 2021-07-02 | 2021-07-01 | GYRE | Ling Geoffrey M.D. | Dir | A - Grant | $0.00 | +2,713 | 16.1K | +20% | $0 |
| D | 2021-07-02 | 2021-07-01 | GYRE | Williams Eddie | Dir | A - Grant | $0.00 | +1,414 | 19.5K | +8% | $0 |
| D | 2021-07-02 | 2021-07-01 | GYRE | DESOUZA ERROL B | Dir | A - Grant | $0.00 | +3,406 | 26.2K | +15% | $0 |
| D | 2021-07-02 | 2021-07-01 | GYRE | Hunt Andrea | Dir | A - Grant | $0.00 | +2,886 | 18.9K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations